$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

$ohcs Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024979 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$271.6K	$217.9K	$1.219M
YoY Change	-12.27%		47.34%
Cost Of Revenue	$80.02K	$60.82K	$262.7K
YoY Change	17.38%		141.66%
Gross Profit	$191.6K	$157.1K	$956.2K
YoY Change	-20.64%		33.07%
Gross Profit Margin	70.54%	72.09%	78.45%
Selling, General & Admin	$2.872M	-$149.3K	$9.022M
YoY Change
% of Gross Profit	1498.83%	-94.99%	943.57%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.414K	$149.1K	$349.9K
YoY Change	-96.57%		11.48%
% of Gross Profit	1.78%	94.88%	36.59%
Operating Expenses	$2.872M	-$149.3K	$9.022M
YoY Change	-23.88%		6.67%
Operating Profit	-$2.680M	$306.4K	-$8.066M
YoY Change	-24.1%		4.22%
Interest Expense	$103.8K	-$126.3K	$324.4K
YoY Change	105.28%		106.18%
% of Operating Profit		-41.23%
Other Income/Expense, Net	-$274.1K	-$291.3K	-$1.985M
YoY Change	-18.33%		192.33%
Pretax Income	-$2.954M	-$193.2K	-$10.05M
YoY Change	-23.6%		19.39%
Income Tax		$7.680K	$674.3K
% Of Pretax Income
Net Earnings	-$2.954M	-$200.6K	-$10.73M
YoY Change	-18.92%		38.35%
Net Earnings / Revenue	-1087.63%	-92.05%	-879.92%
Basic Earnings Per Share	-$0.07		-$0.28
Diluted Earnings Per Share	-$0.07	-$0.01	-$0.28
COMMON SHARES
Basic Shares Outstanding	40.17M shares	40.29M shares	38.79M shares
Diluted Shares Outstanding	39.94M shares		38.79M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$594.5K	$1.000M	$1.000M
YoY Change
Cash & Equivalents	$221.7K	$751.0K	$751.0K
Short-Term Investments	$372.8K	$249.1K	$249.1K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$582.6K	$525.1K	$525.1K
Other Receivables	$200.0K	$200.7K	$200.7K
Total Short-Term Assets	$1.377M	$1.726M	$1.726M
YoY Change		-16.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$53.03K	$56.20K	$395.8K
YoY Change		1144.38%
Goodwill	$815.5K	$815.5K
YoY Change		-71.09%
Intangibles	$2.500K	$2.750K
YoY Change		-99.86%
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change
Total Long-Term Assets	$1.194M	$1.214M	$1.214M
YoY Change		-78.74%
TOTAL ASSETS
Total Short-Term Assets	$1.377M	$1.726M	$1.726M
Total Long-Term Assets	$1.194M	$1.214M	$1.214M
Total Assets	$2.571M	$2.940M	$2.940M
YoY Change		-62.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$893.5K	$738.4K	$738.4K
YoY Change		-13.26%
Accrued Expenses	$603.0K	$581.8K	$648.9K
YoY Change		44.83%
Deferred Revenue
YoY Change
Short-Term Debt	$138.9K	$140.3K	$140.3K
YoY Change
Long-Term Debt Due	$5.300K	$5.300K	$5.300K
YoY Change
Total Short-Term Liabilities	$1.709M	$1.533M	$1.533M
YoY Change		8.18%
LONG-TERM LIABILITIES
Long-Term Debt	$3.050M	$2.767M	$2.767M
YoY Change
Other Long-Term Liabilities	$265.7K	$283.1K	$283.1K
YoY Change
Total Long-Term Liabilities	$3.316M	$3.050M	$3.050M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.709M	$1.533M	$1.533M
Total Long-Term Liabilities	$3.316M	$3.050M	$3.050M
Total Liabilities	$5.025M	$4.582M	$4.581M
YoY Change		93.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.99M	-$19.03M
YoY Change		129.1%
Common Stock	$40.22K	$38.29K
YoY Change		45.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.452M	-$1.641M	-$1.641M
YoY Change
Total Liabilities & Shareholders Equity	$2.571M	$2.940M	$2.940M
YoY Change		-62.23%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.954M	-$200.6K	-$10.73M
YoY Change	-18.92%		38.35%
Depreciation, Depletion And Amortization	$3.414K	$149.1K	$349.9K
YoY Change	-96.57%		11.48%
Cash From Operating Activities	-$1.252M	-$1.005M	-$4.037M
YoY Change	63.18%		46.6%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$28.16K	$57.54K
YoY Change
Acquisitions			-$9.000K
YoY Change			-89.05%
Other Investing Activities	$0.00	-$100.0K	$709.0K
YoY Change
Cash From Investing Activities	$0.00	-$128.2K	$651.5K
YoY Change	-100.0%		-141.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.956M
YoY Change			33.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$722.4K	1.203M	$3.876M
YoY Change	-14991.94%		8.95%
NET CHANGE
Cash From Operating Activities	-$1.252M	-1.005M	-$4.037M
Cash From Investing Activities	0.000	-128.2K	$651.5K
Cash From Financing Activities	$722.4K	1.203M	$3.876M
Net Change In Cash	-$529.3K	70.14K	$490.2K
YoY Change	-728.44%		-162.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.252M	-$1.005M	-$4.037M
Capital Expenditures	$0.00	$28.16K	$57.54K
Free Cash Flow	-$1.252M	-$1.033M	-$4.095M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	333-261849
CY2022	dei	Entity Registrant Name EntityRegistrantName	OPTIMUS HEALTHCARE SERVICES, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-0181535
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1400 Old Country Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Westbury
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11590
CY2022	dei	City Area Code CityAreaCode	(516)
CY2022	dei	Local Phone Number LocalPhoneNumber	806-4201
CY2022	dei	Security12b Title Security12bTitle	None
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	21167000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40167598	shares
CY2022	dei	Auditor Firm AuditorFirmId	759
CY2022	dei	Auditor Name AuditorName	Seligson & Giannattasio, LLP
CY2022	dei	Auditor Location AuditorLocation	White Plains, New York
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260838	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	525064	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	474638	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	200689	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104877	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	73546	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	144199	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1327440	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1725846	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2136462	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318717	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4516	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2750	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1899748	usd
CY2022Q4	us-gaap	Goodwill Goodwill	815500	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2820345	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	666616	usd
CY2022Q4	us-gaap	Assets Assets	2939906	usd
CY2021Q4	us-gaap	Assets Assets	7846404	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	738395	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	851309	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581802	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	401723	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	150079	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	617	usd
CY2022Q4	ohcs	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	200	usd
CY2021Q4	ohcs	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	25200	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	5304	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45224	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1532813	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1479456	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	279968	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	2759961	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	663014	usd
CY2022Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	6562	usd
CY2021Q4	us-gaap	Program Rights Obligations Noncurrent ProgramRightsObligationsNoncurrent	11482	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4582428	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2433920	usd
CY2022Q4	ohcs	Preferred Stock Value1 PreferredStockValue1	2	usd
CY2021Q4	ohcs	Preferred Stock Value1 PreferredStockValue1	10001	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	8106	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	8106	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38286598	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38286598	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26225974	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26225974	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	38287	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	26226	usd
CY2022Q4	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	1206	usd
CY2021Q4	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17343671	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13676762	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19032561	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8307686	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1641289	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5413409	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-1233	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-925	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2939906	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7846404	usd
CY2022	us-gaap	Revenues Revenues	1218882	usd
CY2021	us-gaap	Revenues Revenues	827266	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	262689	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	108702	usd
CY2022	us-gaap	Gross Profit GrossProfit	956193	usd
CY2021	us-gaap	Gross Profit GrossProfit	718564	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3315895	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4700222	usd
CY2022	ohcs	Personnel Expenses PersonnelExpenses	2699958	usd
CY2021	ohcs	Personnel Expenses PersonnelExpenses	1581716	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2330568	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1499791	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	675943	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	676613	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9022364	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	8458342	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8066171	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7739778	usd
CY2022	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	1131629	usd
CY2021	ohcs	Amortization Of Financing Cost AmortizationOfFinancingCost	663014	usd
CY2021	us-gaap	Gain Loss On Sales Of Consumer Loans GainLossOnSalesOfConsumerLoans	148975	usd
CY2022	us-gaap	Interest Expense InterestExpense	324385	usd
CY2021	us-gaap	Interest Expense InterestExpense	157330	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-218238	usd
CY2022	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	-127927	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-183241	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-22560	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	700	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	15000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1984720	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-678929	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10050891	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8418707	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	674292	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-666616	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-10725183	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-7752091	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-308	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-312	usd
CY2022	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-10724875	usd
CY2021	ohcs	Net Income Loss Available To Common Stockholder Basic1 NetIncomeLossAvailableToCommonStockholderBasic1	-7751779	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7752091	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38785879	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16993671	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	444353	usd
CY2021	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1460000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4560000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	928762	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	4700222	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	88691	usd
CY2021	ohcs	Fair Value Of Beneficial Conversion Feature FairValueOfBeneficialConversionFeature	982547	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7752091	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5412484	usd
CY2021	ohcs	Gross Unrealized Gain GrossUnrealizedGain		usd
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1956000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	467500	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	111847	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	561100	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3600000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	857835	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	3315895	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10725183	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1642522	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10725183	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7752091	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	349851	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	313814	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3315895	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4700223	usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	148975	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-183241	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-22560	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-218238	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	-127927	usd
CY2021	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1131629	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	663014	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4055	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4717	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	666616	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-666616	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53256	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-112060	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	31331	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2760	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	631537	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	143439	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4037342	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2754054	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-9000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-82157	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2203666	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1503666	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1350000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	311592	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	57540	usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	5061	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	651460	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1584496	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1956000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1460000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1935000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
CY2022	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	4920	usd
CY2021	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	-148975	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10019	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	51477	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3876061	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3557498	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	490179	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-781052	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260838	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1041890	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751017	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260838	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	258000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	ohcs	Stock Issued Business Acquisition StockIssuedBusinessAcquisition	467500	usd
CY2021	ohcs	Stock Issued Business Acquisition StockIssuedBusinessAcquisition	4560000	usd
CY2021	ohcs	Software Development Costs Acquired In Business Combination SoftwareDevelopmentCostsAcquiredInBusinessCombination	2026245	usd
CY2021	ohcs	Fair Values Of Beneficial Conversion Feature FairValuesOfBeneficialConversionFeature	982547	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	857835	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	88691	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	561100	usd
CY2022	ohcs	Common Stock Issued With Convertible Notes Payable CommonStockIssuedWithConvertibleNotesPayable	111847	usd
CY2021	ohcs	Common Stock Issued With Convertible Notes Payable CommonStockIssuedWithConvertibleNotesPayable	928762	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optimus Healthcare Services, Inc. (formerly Between Dandelions, Inc., “Optimus”, “Company”) was initially organized under the laws of Florida on February 26, 1990, as Phoenix Management Associates, Inc. Over the ensuing years, the Company made a series of amendments to its Articles of Incorporation relating to authorization of various series of Preferred Shares and made a series of name changes. The current name of Optimus Healthcare Services, Inc. became effective with the State of Florida on January 24, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is dedicated to: (1) advancing access to clinical trial research; and (2) improving and simplifying access to vaccines and pharmaceutical products. Currently the Company provides these services through its portfolio companies, Clinical Research Alliance, Inc. (CRA), and Worker’s Health Rx (d/b/a Vitality Rx).</p>
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022Q4	ohcs	No Coupon Due On Demand Issued Two NoCouponDueOnDemandIssuedTwo		usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of equity issued for services, valuation of equity associated with convertible debt, the valuation of derivative liabilities, and the valuation of deferred tax assets. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"> </p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration:underline">Reclassification</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts included in prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s previously reported financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “<i>Revenue from contracts with customers,”</i> (Topic 606). Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. The Company’s main revenue stream is from services. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon delivery. For services performed by CRA, the Company’s performance obligations are generally met at the point in time the services are rendered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	119268	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	58726	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	339614	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	318717	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in certificates of deposit, deposit accounts or treasury bills. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260838	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	363153	usd
CY2021	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	0	usd
CY2022	ohcs	Annual Revenues Costomer Percentage AnnualRevenuesCostomerPercentage	0.571	pure
CY2022Q4	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	3500000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3627927	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty	127927	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3315895	usd
CY2022	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	3315895	usd
CY2021	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	4700222	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	51088	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022	ohcs	Warrants Warrants	1705000	shares
CY2021	ohcs	Warrants Warrants	165000	shares
CY2022	ohcs	Stock Options StockOptions	1112500	shares
CY2022	ohcs	Convertible Notes Payable Shares ConvertibleNotesPayableShares	4400000	shares
CY2021	ohcs	Convertible Notes Payable Shares ConvertibleNotesPayableShares	2200000	shares
CY2022	us-gaap	Auction Market Preferred Securities Shares Issued AuctionMarketPreferredSecuritiesSharesIssued	406664	shares
CY2021	us-gaap	Auction Market Preferred Securities Shares Issued AuctionMarketPreferredSecuritiesSharesIssued	12905287	shares
CY2022	ohcs	Totalshares Totalshares	7624164	shares
CY2021	ohcs	Totalshares Totalshares	15270287	shares
CY2022	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	179	usd
CY2022	ohcs	Interest Rate Of Lease InterestRateOfLease	0.075	pure
CY2022Q4	ohcs	Office Lease OfficeLease	456819	usd
CY2021Q4	ohcs	Office Lease OfficeLease	371832	usd
CY2022Q4	ohcs	Equipment Lease EquipmentLease	2063	usd
CY2021Q4	ohcs	Equipment Lease EquipmentLease	5611	usd
CY2022Q4	ohcs	Office Lease Liability OfficeLeaseLiability	348081	usd
CY2021Q4	ohcs	Office Lease Liability OfficeLeaseLiability	321214	usd
CY2022Q4	ohcs	Equipment Lease Liability EquipmentLeaseLiability	2063	usd
CY2021Q4	ohcs	Equipment Lease Liability EquipmentLeaseLiability	3978	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	67052	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45224	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283092	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	279968	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	90970	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	91335	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	93837	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	88269	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	49677	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	414088	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	63944	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	350144	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	751017	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260838	usd
CY2022Q4	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	193033	usd
CY2021Q4	us-gaap	Capital Units Net Amount CapitalUnitsNetAmount	657006	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	10725183	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	7752091	usd
CY2022	ohcs	Going Concern Term GoingConcernTerm	P1Y
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	140060	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	150079	usd
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
CY2020Q4	us-gaap	Debtor In Possession Financing Interest Rate On Borrowings Outstanding DebtorInPossessionFinancingInterestRateOnBorrowingsOutstanding	1	pure
CY2022	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	1
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	1.25
CY2020Q4	ohcs	Business Acquisition Percentage Of Voting Interest Acquired BusinessAcquisitionPercentageOfVotingInterestAcquired	0.73	pure
CY2021Q4	us-gaap	Memberships In Exchanges Owned MembershipsInExchangesOwned	425000	usd
CY2022	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	815500	usd
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	2000000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	400000	shares
CY2022Q4	us-gaap	Loans Payable LoansPayable	200000	usd
CY2022Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	100000	usd
CY2022Q4	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3600000	usd
CY2022Q4	us-gaap	Beneficial Interest BeneficialInterest	100000	usd
CY2022Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	200689	usd
CY2022Q4	ohcs	Aggregate Principal Amount AggregatePrincipalAmount	200000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56696	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	11555	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	23896	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	3904	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80592	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15459	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24396	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10943	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56196	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4516	usd
CY2022	us-gaap	Depreciation Depreciation	3948	usd
CY2022	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0164	pure
CY2022	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	10019	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4700222	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	6247006	usd
CY2022	us-gaap	Stock Option Down Round Feature Increase Decrease In Equity Amount1 StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount1	2931111	usd
CY2021	us-gaap	Development Costs DevelopmentCosts	2026245	usd
CY2022	ohcs	Website Website	3000	usd
CY2022Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	250	usd
CY2021Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	126497	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2750	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1899748	usd
CY2022	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	345903	usd
CY2021	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	0	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	327440	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1350000	usd
CY2022	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	-183241	usd
CY2021	ohcs	Gross Unrealized Loss GrossUnrealizedLoss	-22560	usd
CY2022	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	144199	usd
CY2021	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	1327440	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	183241	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	22560	usd
CY2022	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	203371	usd
CY2021	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	20130	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	69269	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	46709	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	617	usd
CY2021Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	617	usd
CY2022Q4	ohcs	Notes Payable Related Parties Classified As Current NotesPayableRelatedPartiesClassifiedAsCurrent	200	usd
CY2021Q4	ohcs	Notes Payable Related Parties Classified As Current NotesPayableRelatedPartiesClassifiedAsCurrent	25200	usd
CY2011Q1	ohcs	Issued1 Issued1	10000	usd
CY2021Q4	ohcs	No Coupon Due On Demand Issued One NoCouponDueOnDemandIssuedOne	10000	usd
CY2016Q4	ohcs	Issued2 Issued2	15000	usd
CY2021Q4	ohcs	No Coupon Due On Demand Issued Two NoCouponDueOnDemandIssuedTwo	15000	usd
CY2020Q4	ohcs	Issued3 Issued3	10100	usd
CY2022Q4	ohcs	No Coupon Due On Demand Issued Three NoCouponDueOnDemandIssuedThree	200	usd
CY2021Q4	ohcs	No Coupon Due On Demand Issued Three NoCouponDueOnDemandIssuedThree	200	usd
CY2022Q4	ohcs	Notes Payable Related Parties NotesPayableRelatedParties	200	usd
CY2021Q4	ohcs	Notes Payable Related Parties NotesPayableRelatedParties	25200	usd
CY2022Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	362000	shares
CY2022Q3	us-gaap	Other Notes Payable OtherNotesPayable	25000	usd
CY2022Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	296839	usd
CY2022	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	218238	usd
CY2020Q4	ohcs	Cancelled Shares CancelledShares	9998889	shares
CY2020Q2	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	145683	usd
CY2021Q1	us-gaap	Loans Receivable With Fixed Rates Of Interest1 LoansReceivableWithFixedRatesOfInterest1	148975	usd
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
CY2020Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	126546	usd
CY2022	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	The unforgiven portion of the PPP loan totaling $19,137 is payable over five years at an interest rate of 1%, with a deferral of payments for the first twelve months.
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	6562	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	5304	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	148975	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2759961	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	663014	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2021Q2	us-gaap	Debt Instrument Description DebtInstrumentDescription	On May 25, 2021, the Company entered into a securities purchase agreement with certain institutional investors (collectively, the “May 2021 Investors”) pursuant to which the Company issued convertible notes in an aggregate principal amount of $2,200,000 for an aggregate purchase price of $2 million (collectively, the “May 2021 Notes”). In connection with the issuance of the May 2021 Notes, the Company issued to the May 2021 Investors warrants to purchase an aggregate of 165,000 shares of common stock (collectively, the “Warrants”) and 1,727,859 shares of common stock. The May 2021 Notes accrue interest at a rate of 9% per annum, subject to increase to 20% per annum upon and during the occurrence of an event of default. Interest is payable in cash on a quarterly basis. The May 2021 Notes are convertible at any time, at the holder’s option, into shares of the Company’s common stock at a conversion price of $1.00 per share, subject to certain beneficial ownership limitations (with a maximum ownership limit of 9.99%). The conversion price is also subject to adjustment due to certain events, including stock dividends and stock splits. On June 7, 2022, the Company entered into an amendment to modify the maturity date of the May 2021 Notes from May 25, 2023 to May 25, 2024. The Company tested the modification under ASC 470-50-40 to determine if the modification resulted in an extinguishment. It was determined the present value of the cash flows under the terms of the new debt instrument was not at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. As a result, the modification did not result in a loss on an extinguishment. Each Warrant is exercisable for a period of five years from the date of issuance at an initial exercise price of $1.25 per share, subject to certain beneficial ownership limitations (with a maximum ownership limit of 9.99%).
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2200000	usd
CY2022Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2200000	usd
CY2022Q2	ohcs	Aggregate Purchase Price AggregatePurchasePrice	2000000	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1
CY2022Q2	ohcs	Equity Method Investments Ownership Percentages EquityMethodInvestmentsOwnershipPercentages	0.0999	pure
CY2022	ohcs	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerms	P5Y
CY2022	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.25
CY2022Q4	ohcs	Equity Method Investments Ownership Percentages EquityMethodInvestmentsOwnershipPercentages	0.0999	pure
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	314600	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	121000	usd
CY2022	ohcs	Amortization Of Debt Discount AmortizationOfDebtDiscount	1131629	usd
CY2021	ohcs	Amortization Of Debt Discount AmortizationOfDebtDiscount	663014	usd
CY2021Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	1
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4091000	shares
CY2022	ohcs	Raised Pursuant Amount RaisedPursuantAmount	1956000	usd
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	9998899	shares
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
CY2022	ohcs	Balance As Of Stock Options BalanceAsOfStockOptions	3365000	usd
CY2022Q4	us-gaap	Share Price SharePrice	1.72
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.3404	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0328	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5297500	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.74
CY2021	ohcs	Weighted Average Remaining Term Options Granted WeightedAverageRemainingTermOptionsGranted	P10Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5297500	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.74
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y5M4D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3365000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.72
CY2022	ohcs	Weighted Average Remaining Term Options Granted WeightedAverageRemainingTermOptionsGranted	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2767500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.8
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5895000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.69
CY2022	ohcs	Weighted Average Remaining Term Options Outstanding At Ending Balance WeightedAverageRemainingTermOptionsOutstandingAtEndingBalance	P9Y1M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1112500	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.67
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6298930	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	2000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2000000	shares
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	165000	shares
CY2021	ohcs	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	1.25
CY2021	ohcs	Weighted Average Remaining Term Issued WeightedAverageRemainingTermIssued	P5Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	165000	shares
CY2021	ohcs	Weighted Average Average Exercise Price Ending Balance WeightedAverageAverageExercisePriceEndingBalance	1.25
CY2021	ohcs	Weighted Average Remaining Term Ending Balance1 WeightedAverageRemainingTermEndingBalance1	P4Y4M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1540000	shares
CY2022	ohcs	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	1.25
CY2022	ohcs	Weighted Average Remaining Term Issued WeightedAverageRemainingTermIssued	P5Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1705000	shares
CY2022	ohcs	Weighted Average Average Exercise Price Ending Balance WeightedAverageAverageExercisePriceEndingBalance	1.25
CY2022	ohcs	Weighted Average Remaining Term Ending Balance1 WeightedAverageRemainingTermEndingBalance1	P4Y4M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1705000	shares
CY2022	ohcs	Weighted Average Average Exercise Price Warrants Exercisable WeightedAverageAverageExercisePriceWarrantsExercisable	1.25
CY2022	ohcs	Weighted Average Remaining Term Warrants Exercisable1 WeightedAverageRemainingTermWarrantsExercisable1	P4Y4M2D
CY2021Q4	ohcs	Debt Conversion Converted Instrument Amount2 DebtConversionConvertedInstrumentAmount2	425000	usd
CY2021Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	425000	shares
CY2021Q4	ohcs	Equity Method Investment Ownership Percentages EquityMethodInvestmentOwnershipPercentages	1	pure
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7751779	usd
CY2021	ohcs	Increase In Optimus Healthcare Services Inc Ownership Interests In Craac From51 To9988 IncreaseInOptimusHealthcareServicesIncOwnershipInterestsInCRAACFrom51To9988	-274400	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8026179	usd
CY2022	ohcs	Software Development Costs Acquired In Business Combination SoftwareDevelopmentCostsAcquiredInBusinessCombination		usd
CY2022	ohcs	Fair Values Of Beneficial Conversion Feature FairValuesOfBeneficialConversionFeature		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	ohcs	Stock Options StockOptions		shares
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7676	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7676	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	666616	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-666616	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	666616	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-666616	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	674292	usd
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-666616	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.0646	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.1172	pure
CY2022	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0302	pure
CY2021	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0196	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0002	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.151	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0128	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0432	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0059	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.067	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0791	pure
CY2021Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure		usd
CY2021	us-gaap	Depreciation Depreciation		usd
CY2022	us-gaap	Development Costs DevelopmentCosts		usd
CY2021	ohcs	Website Website		usd
CY2022	ohcs	Gross Unrealized Gain GrossUnrealizedGain		usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1393319	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	601151	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	198703	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	91510	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	68290	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	51345	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	53151	usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	12553	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	54941	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	6826	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1155	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	59113	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1857563	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	734494	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7172	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	948	usd
CY2022Q4	ohcs	Right Of Use Asset RightOfUseAsset	88758	usd
CY2021Q4	ohcs	Right Of Use Asset RightOfUseAsset	-66930	usd
CY2022Q4	ohcs	Deferred Income Tax Liabilitie DeferredIncomeTaxLiabilitie	-81586	usd
CY2021Q4	ohcs	Deferred Income Tax Liabilitie DeferredIncomeTaxLiabilitie	67878	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1775977	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	666616	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1775977	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	666616	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6634850	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16993671	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38785879	shares
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities		usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable		usd
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	ohcs	Weighted Average Remaining Term Options Exercised WeightedAverageRemainingTermOptionsExercised
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	ohcs	Weighted Average Remaining Term Options Cancelled WeightedAverageRemainingTermOptionsCancelled
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	ohcs	Weighted Average Remaining Term Options Exercised WeightedAverageRemainingTermOptionsExercised
CY2022	ohcs	Weighted Average Remaining Term Options Cancelled WeightedAverageRemainingTermOptionsCancelled
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2021	ohcs	Weighted Average Average Exercise Price Beginning Balance WeightedAverageAverageExercisePriceBeginningBalance
CY2021	ohcs	Weighted Average Remaining Term Beginning Balance WeightedAverageRemainingTermBeginningBalance
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2021	ohcs	Weighted Average Average Exercise Price Exercised WeightedAverageAverageExercisePriceExercised
CY2021	ohcs	Weighted Average Remaining Term Exercised WeightedAverageRemainingTermExercised
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2021	ohcs	Weighted Average Average Exercise Price Expired WeightedAverageAverageExercisePriceExpired
CY2021	ohcs	Weighted Average Remaining Term Expired WeightedAverageRemainingTermExpired
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	ohcs	Weighted Average Average Exercise Price Exercised WeightedAverageAverageExercisePriceExercised
CY2022	ohcs	Weighted Average Remaining Term Exercised WeightedAverageRemainingTermExercised
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	ohcs	Weighted Average Average Exercise Price Expired WeightedAverageAverageExercisePriceExpired
CY2022	ohcs	Weighted Average Remaining Term Expired WeightedAverageRemainingTermExpired
CY2021	ohcs	Transfersto From The Noncontrolling Interest TransferstoFromTheNoncontrollingInterest		usd
CY2021	ohcs	Net Transfers Fromto Noncontrolling Interest NetTransfersFromtoNoncontrollingInterest		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001892025

Files In Submission

Name	View Source	Status
0001213900-23-024979-index-headers.html	Edgar Link	pending
0001213900-23-024979-index.html	Edgar Link	pending
0001213900-23-024979.txt	Edgar Link	pending
0001213900-23-024979-xbrl.zip	Edgar Link	pending
f10k2022ex21-1_optimushealth.htm	Edgar Link	pending
f10k2022ex31-1_optimushealth.htm	Edgar Link	pending
f10k2022ex31-2_optimushealth.htm	Edgar Link	pending
f10k2022ex32-1_optimushealth.htm	Edgar Link	pending
f10k2022ex32-2_optimushealth.htm	Edgar Link	pending
f10k2022ex4-6_optimushealth.htm	Edgar Link	pending
f10k2022_optimushealth.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ohcs-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ohcs-20221231_def.xml	Edgar Link	unprocessable
ohcs-20221231_cal.xml	Edgar Link	unprocessable
ohcs-20221231_lab.xml	Edgar Link	unprocessable
ohcs-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_optimushealth_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs

2023 Q1 Form 10-K Financial Statement

#000121390023024979 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS Optimus Healthcare Services, Inc. Stock $ohcs

2023 Q1 Form 10-K Financial Statement

#000121390023024979 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OHCS
Optimus Healthcare Services, Inc. Stock $ohcs